 |
|
|
| |
(HepDart) SURVEYOR-II: High SVR4 Rates Achieved With the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530 In Non-Cirrhotic Treatment-Naïve and Treatment-Experienced Patients With HCV Genotype 3 Infection
|
| |
| |
Reported by Jules Levin
HepDart 2015
Frontiers in Drug Development for Viral Hepatitis, December 6 - 10, 2015, Wailea, Hawaii
Paul Kwo,1 Michael Bennett,2 Stanley Wang,3 Hugo E. Vargas,4 David Wyles,5 J. Scott Overcash,6 Peter Ruane,7 Benedict Maliakkal,8 Asma Siddique,9 Bal Raj Bhandari,10 Fred Poordad,11 Ran Liu,3 Chih-Wei Lin,3 Teresa I. Ng,3 Federico J. Mensa,3 Jens Kort3
1Indiana University School of Medicine, Indianapolis, IN, USA; 2San Diego Digestive Disease Consultants, Inc., and Medical Associates Research Group, Inc., San Diego, CA, USA; 3AbbVie Inc., North Chicago, IL, USA; 4Mayo Clinic, Phoenix, AZ, USA; 5University of California San Diego, La Jolla, CA, USA; 6eStudySite, San Diego, CA, USA; 7Ruane Medical & Liver Health Institute, Los Angeles, CA, USA; 8University of Rochester Medical Center, Rochester, NY, USA; 9Virginia Mason Hospital and Medical Center, Seattle, WA, USA; 10Gastroenterology & Nutritional Medical Services, Bastrop, LA, USA; 11Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA
AASLD: 100% SVR4 in HCV Genotype 1 Non-Cirrhotic Treatment-Naïve or -Experienced Patients With the Combination of ABT-493 and ABT-530 for 8 Weeks (SURVEYOR-I)....[8 weeks] - (11/17/15)
AASLD: SURVEYOR-I: 98% - 100% SVR4 in HCV Genotype 1 Non-Cirrhotic Treatment-Naïve or Pegylated Interferon/Ribavirin Null-Responders with the Combination of the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530 - (11/16/15)
AASLD: SURVEYOR-II: High SVR4 Rates Achieved With the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530 in Non-Cirrhotic Treatment-Naïve and Treatment-Experienced Patients With HCV Genotype 2 Infection - (12/01/15)
AASLD: QUARTZ-I: Retreatment of HCV Genotype 1 DAA-failures With Ombitasvir/Paritaprevir/r, Dasabuvir, and Sofosbuvir - (11/17/15)
AASLD: ABBVIE ANNOUNCES HIGH SUSTAINED VIROLOGIC RESPONSE RATES IN PHASE 2 STUDIES WITH PAN-GENOTYPIC, INVESTIGATIONAL REGIMEN IN PATIENTS WITH CHRONIC HEPATITIS C - (11/19/15)
|
| |
|
|
|
|
|
